ABBV-CLS-484

AssetAlso osunprotafib

Inhibits PTPN2 and PTPN1 for cancer immunotherapy.

Stage: Phase 1
Modality: Not known
Target: Not known; 1
Indication: 0
Trials: 1
Developer

Indications

1

Locally advanced or metastatic tumors
Phase 1, calicolabs.com, 10 Oct 2026

In the full profile

Owner and partners1

Every asset’s record: target, stage, trials and the evidence behind it.